AU2020377872B2 - Treatment for Sjogren's Syndrome - Google Patents

Treatment for Sjogren's Syndrome Download PDF

Info

Publication number
AU2020377872B2
AU2020377872B2 AU2020377872A AU2020377872A AU2020377872B2 AU 2020377872 B2 AU2020377872 B2 AU 2020377872B2 AU 2020377872 A AU2020377872 A AU 2020377872A AU 2020377872 A AU2020377872 A AU 2020377872A AU 2020377872 B2 AU2020377872 B2 AU 2020377872B2
Authority
AU
Australia
Prior art keywords
ser
antibody
leu
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020377872A
Other languages
English (en)
Other versions
AU2020377872A1 (en
Inventor
Irina BALTCHEVA
Wolfgang Hueber
Stephen Oliver
Olivier PETRICOUL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2020377872A1 publication Critical patent/AU2020377872A1/en
Priority to AU2025202534A priority Critical patent/AU2025202534A1/en
Application granted granted Critical
Publication of AU2020377872B2 publication Critical patent/AU2020377872B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020377872A 2019-11-06 2020-10-23 Treatment for Sjogren's Syndrome Active AU2020377872B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202534A AU2025202534A1 (en) 2019-11-06 2025-04-09 Treatment for sjogren's syndrome

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931292P 2019-11-06 2019-11-06
US62/931,292 2019-11-06
PCT/US2020/057184 WO2021091706A1 (en) 2019-11-06 2020-10-23 Treatment for sjögren's syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202534A Division AU2025202534A1 (en) 2019-11-06 2025-04-09 Treatment for sjogren's syndrome

Publications (2)

Publication Number Publication Date
AU2020377872A1 AU2020377872A1 (en) 2022-05-26
AU2020377872B2 true AU2020377872B2 (en) 2025-04-24

Family

ID=73449232

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020377872A Active AU2020377872B2 (en) 2019-11-06 2020-10-23 Treatment for Sjogren's Syndrome
AU2025202534A Pending AU2025202534A1 (en) 2019-11-06 2025-04-09 Treatment for sjogren's syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202534A Pending AU2025202534A1 (en) 2019-11-06 2025-04-09 Treatment for sjogren's syndrome

Country Status (7)

Country Link
US (1) US20220356261A1 (https=)
EP (1) EP4055047A1 (https=)
JP (2) JP2023501781A (https=)
KR (1) KR20220093347A (https=)
AU (2) AU2020377872B2 (https=)
CA (1) CA3160207A1 (https=)
WO (1) WO2021091706A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021320129B2 (en) * 2020-08-04 2025-12-18 Novartis Ag Treatment of B cell malignancies
WO2025083621A1 (en) * 2023-10-20 2025-04-24 Novartis Ag Treatment of hidradenitis suppurativa using anti-baff-r antibodies
WO2025257781A1 (en) * 2024-06-14 2025-12-18 Novartis Ag Treatment of systemic sclerosis using anti-baff-r antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513100A (pt) * 2004-07-22 2007-10-23 Genentech Inc métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9833519B2 (en) * 2012-09-25 2017-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for the diagnosis and treatment of sjögren's syndrome
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DÖRNER THOMAS ET AL: "Treatment of primary Sjögren's syndrome with ianalumab (VAY736)...", Annals of the Rheumatic Diseases, 2019, vol. 78, no. 5, pages 641 - 647 *
SIMON BOWMAN ET AL: "Ianalumab (VAY736), a Dual Mode of Action Biologic...", ARTHRITIS RHEUMATOL, vol. 71 (suppl 10) 2019 *

Also Published As

Publication number Publication date
AU2020377872A1 (en) 2022-05-26
JP2026062653A (ja) 2026-04-10
KR20220093347A (ko) 2022-07-05
EP4055047A1 (en) 2022-09-14
JP2023501781A (ja) 2023-01-19
WO2021091706A1 (en) 2021-05-14
AU2025202534A1 (en) 2025-05-01
US20220356261A1 (en) 2022-11-10
CA3160207A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
AU2025202534A1 (en) Treatment for sjogren's syndrome
AU2019226551B2 (en) Methods for altering body composition
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
US12528868B2 (en) CD1a antibodies and uses thereof
TW202239767A (zh) 用於治療類風濕性關節炎之組成物及方法
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
KR102628314B1 (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
KR20240004760A (ko) 항-baffr 항체를 사용한 루푸스 신염의 치료
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
TW202302146A (zh) 使用抗baffr抗體治療全身性紅斑狼瘡

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)